Adaptimmune Therapeutics (ADAP) Expected to Announce Quarterly Earnings on Wednesday

Adaptimmune Therapeutics (NASDAQ:ADAP) is projected to post its quarterly earnings results before the market opens on Wednesday, March 5th. Analysts expect Adaptimmune Therapeutics to post earnings of ($0.15) per share for the quarter.

Adaptimmune Therapeutics Trading Down 5.4 %

NASDAQ ADAP opened at $0.51 on Tuesday. Adaptimmune Therapeutics has a 52 week low of $0.51 and a 52 week high of $2.05. The stock has a market cap of $130.68 million, a P/E ratio of -2.32 and a beta of 2.42. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. The company’s fifty day simple moving average is $0.59 and its 200-day simple moving average is $0.77.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Mizuho reduced their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a report on Wednesday, November 27th. StockNews.com lowered Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Guggenheim reduced their price objective on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday, November 15th. Finally, HC Wainwright dropped their price target on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Adaptimmune Therapeutics has an average rating of “Buy” and an average target price of $2.79.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.